RxDoctor Payments Data

Jonathan Rogers, MD

Cardiovascular Disease · Baltimore, MDNPI 1619012291

Payments from drug & device makers

$8,435in general payments, 2019–2025

Across 458 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • Novartis$979
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$633
  • Johnson & Johnson$629
  • E.r. Squibb & Sons, L.L.C.$609
  • Amgen$461
  • plus $4K from 36 others

What the payments were for

  • Consulting fees$390%
  • Food & beverage$8,396100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,435 in reported general payments places this provider in the 75th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$1,801,804
Medicare patients
2,076
Services billed
10,621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban282$356,625
EntrestoSacubitril/Valsartan121$158,590
XareltoRivaroxaban57$64,017
JardianceEmpagliflozin23$26,581
Repatha SureclickEvolocumab14$20,707
Metoprolol Succinate451$8,228
Praluent PenAlirocumab13$6,148
Atorvastatin Calcium188$3,091
Dabigatran EtexilateDabigatran Etexilate Mesylate15$2,999
Clonidine26$2,639
Rosuvastatin Calcium167$2,272
Ezetimibe59$1,950
Nebivolol Hcl34$1,888
Ranolazine ErRanolazine19$1,506
Metoprolol Tartrate135$1,472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,048$356,625282 claims
NovartisEntresto$979$158,590121 claims
Johnson & JohnsonXarelto$629$64,01757 claims
Boehringer IngelheimJardiance$302$26,58123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →